LLM returned non-JSON response. Review the filing manually.
Executive Summary
{ "summary": "Wells Fargo's Q1 2026 13F shows a defensive rotation: trimming $6.1B in SPY and reducing exposure to gold miners (GDX) and select industrials, while adding to fixed-income ETFs (HYG, MINT, VGSH, VGIT, JPIE, PYLD, VUSB) and regional banks (KRE, PNC). The fund also initiated a new position in AstraZeneca (CUSIP G0593M107) but fully exited a separate AstraZeneca holding (AZN), resulting in a net reduction. These moves suggest a cautious, yield-oriented posture amid macroeconomic uncer
Financial Impact
Unknown
Risk Factors
- Analysis may be incomplete
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| 13F-CHANGES Data (Synthetic) | 13f-changes-0000072971-2026-Q1 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers